Nezutatug vs Patritumab Deruxtecan

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: HER3 · full Non-Small Cell Lung Cancer pipeline

Nezutatug

Developed by Hummingbird Bioscience

Phase 1/2 in Non-Small Cell Lung Cancermonoclonal antibody
Weak signal

NCT05057013 · Phase 1/2 · active, not recruiting

The trial has no randomization, no blinding, and no control or comparator arm — it is a dose-escalation safety study designed to find a tolerable dose, not to test efficacy against a comparator. While outside reporting shows no dose-limiting toxicities were seen across six dose cohorts, this is a single-arm safety observation with no statistical comparison, so it cannot count as strong or even moderate clinical evidence of efficacy.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: December 2027 · NCT05910827 (registry estimate)

Reported efficacy

Number of Participants Who Experienced Dose Limiting Toxicities (DLTs); Part A (From first dose onwards until completion of Cycle 1 (28 days)); Number of Participants Who Experienced DLTs; Part B Arm 1 (From first dose of combination therapy onwards until completion of Cycle 1 (28 days)); Number of adverse events (AEs) by arm considered to be at least possibly related to HMBD-001 (Part A and Part B Arm 1) (From the date of written informed consent until the end of the safety follow-up period (maximum [max] 42 weeks per participant)); Number of Grade 3, 4 and 5 AEs by arm considered to be at least possibly related to HMBD-001 (Part A and Part B Arm 1) (From the date of written informed consent until the end of the safety follow-up period (max 42 weeks per participant)); Overall response rate (ORR) within 6 cycles of HMBD-001 (Part B Arm 1) (From baseline radiological disease assessment until 28 days after last dose of HMBD-001 (max 36 weeks per participant)): HMBD-001 (NCT05057013), Part A dose escalation: cleared six monotherapy cohorts with no dose-limiting toxicities (DLTs). (not_applicable)

Result source: NCT05057013

Patritumab Deruxtecan

Developed by Daiichi Sankyo and partners

Phase 3 in Non-Small Cell Lung Cancerantibody-drug conjugate
Weak signal

NCT05865990 · Phase 2 · completed

The study used a single-arm, open-label design with no placebo or active comparator, so responses cannot be reliably separated from the natural course of disease or other factors. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: August 2029 · NCT07286149 (registry estimate)

Reported efficacy

Efficacy: Local determination of intracranial objective response rate (ORR-IC) in cohort 1 and cohort 2. (From baseline to the date of first documented progression, death from any cause, or treatment discontinuation from any reason, whichever came first, assessed up to 12 months); Efficacy: Overall survival (OS) rate at 3 months in cohort 3. (From baseline up to 3 months): LMD cohort primary endpoint met: 3-month OS rate 65% (Kaplan-Meier estimate 69.6%, 95% CI 52.0-93.2, P < 0.001) (met)

Result source: NCT05865990

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointNezutatugPatritumab Deruxtecan
PFS, median—Not reported—Trial running · NCT05338970
OS, median—Not reported—Trial running · NCT05338970
ORR—Not reported—Trial running · NCT05338970
Duration of response, median—Not reported—Trial running · NCT05338970

PFS, median

Nezutatug
—Not reported
Patritumab Deruxtecan
—Trial running · NCT05338970

OS, median

Nezutatug
—Not reported
Patritumab Deruxtecan
—Trial running · NCT05338970

ORR

Nezutatug
—Not reported
Patritumab Deruxtecan
—Trial running · NCT05338970

Duration of response, median

Nezutatug
—Not reported
Patritumab Deruxtecan
—Trial running · NCT05338970
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Nezutatug
HMBD-001 (NCT05057013), Part A dose escalation: cleared six monotherapy cohorts with no dose-limiting toxicities (DLTs). NCT05057013 · Phase 1/2 · design grade: weak · publication or press release
Patritumab Deruxtecan
LMD cohort primary endpoint met: 3-month OS rate 65% (Kaplan-Meier estimate 69.6%, 95% CI 52.0-93.2, P < 0.001) NCT05865990 · Phase 2 · design grade: weak · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Nezutatug's landscape · Patritumab Deruxtecan's landscape